SCHEMBL24327435

SCHEMBL24327435

COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(N)n1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 15/20 0.77
INSR P06213 13/20 0.77
IGF1R P08069 13/20 0.77
EGFR P00533 7/20 0.69
MET P08581 3/20 0.68
CHEK1 O14757 2/20 0.68
AURKA O14965 2/20 0.68
NUAK1 O60285 2/20 0.68
JAK2 O60674 2/20 0.68
STK10 O94804 2/20 0.68
PRKD3 O94806 2/20 0.68
CHEK2 O96017 2/20 0.68
ABL1 P00519 2/20 0.68
ERBB2 P04626 2/20 0.68
LCK P06239 2/20 0.68
FYN P06241 2/20 0.68
FES P07332 2/20 0.68
CSF1R P07333 2/20 0.68
YES1 P07947 2/20 0.68
LYN P07948 2/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30378262 1.00 ALK (0.77) ALKINSRIGF1REGFRMET
SCHEMBL18491223 0.92 EGFR (0.73) ALKINSRIGF1REGFRJAK2
SCHEMBL26090325 0.89 ALK (0.82) ALKINSRIGF1REGFRMET
SCHEMBL30377906 0.89 ALK (0.86) ALKINSRIGF1REGFRMET
SCHEMBL26087740 0.89 ALK (0.86) ALKINSRIGF1REGFRMET
SCHEMBL21847021 0.87 INSR (0.88) ALKINSRIGF1REGFRMET
SCHEMBL15217790 0.87 INSR (1.00) ALKINSRIGF1REGFRMET
SCHEMBL26087590 0.87 ALK (0.73) ALKINSRIGF1REGFRMET
SCHEMBL24590541 0.87 ALK (0.60) ALKINSRIGF1REGFRMET
SCHEMBL30378164 0.86 INSR (0.79) ALKINSRIGF1REGFRMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240409609-A1 REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF TERREMOTO BIOSCIENCES, INC. 2024-12-12 US disclosed
WO-2023070114-A2 REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF TERREMOTO BIOSCIENCES, INC. (US) 2023-04-27 WO disclosed
WO-2023070114-A2 REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF TERREMOTO BIOSCIENCES, INC. (US) 2023-04-27 WO disclosed
WO-2022063106-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEIGENE, LTD. (KY) 2022-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240409609-A1 REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF EGFR, ERBB2, ERBB3 ALK 174/4885INSR 2993/4885IGF1R 652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.